Changes in vascular endothelial growth factor level in Helicobacter pylori-associated gastroduodenal diseases
- Authors: Matveeva L.V.1, Kapkaeva R.H.1, Chudaikin A.N.1, Soldatova A.A.1, Mosina L.M.1, Kostina Y.A.1, Solodovnikova G.A.1
-
Affiliations:
- National Research Mordovia State University
- Issue: Vol 12, No 1 (2022)
- Pages: 165-171
- Section: SHORT COMMUNICATIONS
- Submitted: 16.12.2020
- Accepted: 31.10.2021
- Published: 03.12.2021
- URL: https://iimmun.ru/iimm/article/view/1654
- DOI: https://doi.org/10.15789//2220-7619-CIV-1654
- ID: 1654
Cite item
Full Text
Abstract
A populational infection with Helicobacter (H.) pylori poses a global problem. Mucosal colonization of H. pylori in the gastroduodenal area can initiate development multiple diseases with hyper- or hypoplasia of mucosal epithelial cells secreting vascular endothelial growth factor (VEGF). The aim of the study was to assess VEGF serum level, its diagnostic and prognostic value in diseases affecting the gastroduodenal area. Materials and methods. 180 patients with exacerbated chronic gastritis, gastric ulcer, duodenal ulcer as well as 30 healthy volunteers were examined after providing an informed consent. Patients were divided into groups depending on the degree of mucous contamination with H. pylori. In the subjects examined during esophagogastroduodenoscopy, a biological material was collected during targeted biopsy for microscopic and histological studies. Blood samples for immunological examination were obtained in the morning on an empty stomach from the ulnar vein in the volume of 5 ml, and the serum was isolated by centrifugation. The level of VEGF, pepsinogens, and titer of total antibodies against the H. pylori cytotoxin-associated protein were determined in the blood serum from the subjects by using the enzyme immunoassay method. The long-term prognosis was analyzed for up to 2 years. The data obtained were processed statistically. Results. Patients were found to have excessive serum VEGF levels in healthy volunteers. For gastric ulcer associated with H. pylori, 80% of cases had increased discriminatory VEGF level. In patients, direct relationships between the serum VEGF level and degree, stage of gastritis, the degree of contamination with H. pylori, the serum pepsinogens level were uncovered. Regression analysis found that patients with diseases targeting gastroduodenal area had serum VEGF level equal to or greater than 231 pg/ml in 60% of cases that correctly predicted an increase in mucosal atrophy. If the amount of VEGF ≥ 373 pg/ml in 91.5% of cases, then ulceration of gastric epithelium developed, whereas for ≥ 396 pg/ml level it was observed in 89% cases with ulceration of the intestinal epithelium. The probability of gastroduodenal bleeding at a serum VEGF level of 408 pg/ml or higher was predicted correctly in 96% of cases. Conclusion. More than 54% of patients with H. pylori-associated chronic gastritis, peptic ulcer disease had level of VEGF significantly exceeding magnitude found in healthy volunteers and the discriminatory level reflects the morphofunctional state of the stomach and duodenum. Assessing serum VEGF level in gastroduodenal diseases can be recommended for predicting development of atrophy, ulceration of the gastric and intestinal epithelium, and gastroduodenal bleeding.
About the authors
L. V. Matveeva
National Research Mordovia State University
Author for correspondence.
Email: MatveevaLjubov1@mail.ru
Ljubov V. Matveeva - PhD, MD (Medicine), Associate Professor, Professor, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
Phone: +7 (8342) 35-25-16. Fax: +7 (8342) 32-19-83.
РоссияR. H. Kapkaeva
National Research Mordovia State University
Email: k-regina-x@mail.ru
PhD (Medicine), Assistant Professor, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияA. N. Chudaikin
National Research Mordovia State University
Email: ch-alex-n13@rambler.ru
Postgraduate Student, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияA. A. Soldatova
National Research Mordovia State University
Email: ashberrya@mail.ru
Postgraduate Student, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияL. M. Mosina
National Research Mordovia State University
Email: larisamosina97@yandex.ru
PhD, MD (Medicine), Professor, Head of the Department of Hospital Therapy, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияYu. A. Kostina
National Research Mordovia State University
Email: bazunova.2013@mail.ru
PhD (Medicine), Associate Professor, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияG. A. Solodovnikova
National Research Mordovia State University
Email: gsol_r@mail.ru
PhD (Chemistry), Associate Professor, Department of Immunology, Microbiology and Virology, Medical Institute, National Research Mordovia State University.
430032, Republic of Mordovia, Saransk, Ulyanov str., 26a.
РоссияReferences
- Исаева Г.Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori // Клиническая микробиология и антимикробная химиотерапия. 2018. Т. 20. № 1. С. 14–23.
- Кононов А.В., Мозговой С.И., Маркелова М.В., Шиманская А.Г. Морфогенез атрофии слизистой оболочки желудка как основа фенотипа хронического гастрита // Архив патологии. 2011. № 3. С. 26–31.
- Матвеева Л.В., Капкаева Р.Х., Чудайкин А.Н., Новикова Л.В. Значение факторов патогенности в инициации иммунного ответа при инфекции Helicobacter pylori // Вестник Российского университета дружбы народов. Серия: Медицина. 2020. Т. 24, № 1. С. 105–114. doi: 10.22363/2313-0245-2020-24-1-105-114
- Осадчук М.А., Балашов Д.В., Осадчук А.М., Кветной И.М. Роль эпителиоцитов, секретирующих сосудистый эндотелиальный фактор роста, панкреатический полипептид и глюкагон, в возникновении опухолевых заболеваний желудка // Клиническая медицина. 2012. Т. 90, № 2. С. 44–49.
- Патент № 2474824 Российская Федерация, МПК G01N33/53 (2006.01). Способ диагностики атрофического гастрита: № 2011146839/15; заявлено 2011.11.17: опубликовано 2013.02.10 / Матвеева Л.В., Мосина Л.М. Патентообладатель: ФГБОУ ВО Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева. 5 с.
- Патент № 2580309 Российская Федерация, МПК G01N 33/50 (2006.01). Способ иммунодиагностики рака желудка: № 2014150804/15; заявлено 2014.12.15: опубликовано 2016.04.10 / Матвеева Л.В., Мосина Л.М., Стенина М.А., Солдатова А.А. Патентообладатель: ФГБОУ ВО Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева. 7 с.
- Поздеев О.К., Поздеева А.О., Валеева Ю.В., Гуляев П.Е. Механизмы взаимодействия Helicobacter pylori c эпителием слизистой оболочки желудка. I. Факторы патогенности, способствующие успешной колонизации // Инфекция и иммунитет. 2018. Т. 8, № 3. С. 273–283. doi: 10.15789/2220-7619-2018-3-273-283
- Ansari S., Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins, 2019, vol. 11, pp. 677–703. doi: 10.3390/toxins11110677
- Ford A.C., Forman D., Hunt R.H., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. Br. Med. J., 2014, vol. 348, pp. 3174–3178. doi: 10.1136/bmj.g3174
- Hirayama Y., Kawai T., Otaki J. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J. Gastroenterol. Hepatol., 2014, vol. 29, no. 4, pp. 16–19. doi: 10.1111/jgh.12795
- Kim N. Immunological reactions on H. pylori infection (Book Chapter). In: Helicobacter pylori. Singapore: Springer Publishing, 2016, pp. 35–52.